Unique spectrum of activating BRAF alterations in prostate cancer.
Alexander Chehrazi-RaffleHanna TukachinskyEamon ToyeSmruthy S SivakumarAlexa B SchrockHannah E BergomHedyeh EbrahimiSumanta Kumar PalTanya Barauskas DorffArchana M AgarwalBrandon A MahalGeoffrey R OxnardJustin H HwangEmmanuel S AntonarakisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Activating BRAF alterations were detected in ~3% of prostate cancers, and most were Class II mutations and rearrangements; BRAF V600 mutations were exceedingly rare. These findings suggest that BRAF activation in prostate cancer is unique from other cancers and supports further clinical investigation of therapeutics targeting the MAPK pathway.